Analysts are adjusting their Q1 2025 earnings forecasts for several companies, including Workiva, Titan International, Expro Group, Zimmer Biomet, and Zevia PBC. Also, IFP Advisors Inc. reduced its stake in Norwegian Cruise Line Holdings Ltd. Read more...

Analyst updates include lowered EPS estimates for Epsilon Energy (EPSN) by Roth Capital, reduced holdings in Vanguard Mortgage-Backed Securities ETF (VMBS) by IFP Advisors, FY2029 EPS estimates for Schrödinger (SDGR) by Leerink Partnrs, and Q1 2025 earnings estimates for Trulieve Cannabis (TRU) by Roth Capital. Read more...

B. Riley adjusts estimates for several companies, including upgrading New York Mortgage Trust, forecasting UMH Properties' Q1 earnings, and revising earnings per share for Montauk Renewables and Ameresco. Read more...

Recent analyst actions have stirred the tech stock market, with upgrades and downgrades impacting companies like Viridian Therapeutics, Denali, GigaCloud, Intellia, Micron, and VEON. Read more...

A look at the latest earnings estimates and analyst outlook for several companies including Alphabet, Rocket Pharmaceuticals, Pharming Group, Structure Therapeutics, uCloudlink Group, and Longeveron. Read more...

This article summarizes recent market activity, including Whipplewood Advisors' investment in Meta, analyst rating changes for Mattel and Noodles & Company, and Wedbush's updated earnings estimates for Apellis Pharmaceuticals. Read more...

A dying man's estate was left to his hospice nurse, raising questions about potential exploitation and the legal implications of such relationships. Plus, tips for expats investing abroad. Read more...

Scotiabank's recent analyst actions have significantly impacted several companies, with upgrades and downgrades affecting stock prices for firms like AT&T, Janux Therapeutics, and others. Read more...

Zacks Research has released a flurry of updated earnings per share (EPS) estimates for various companies for Q1 2025, impacting firms across diverse sectors. Read more...

Raymond James adjusts its price target for Viant Technology and revises earnings estimates for Elemental Altus Royalties, impacting investor outlook. Read more...

Zscaler's AI-driven growth, Burlington Stores' earnings beat, and analyst adjustments for Ready Capital are among the key market movers. Plus, a strategy for passive income. Read more...

Analyst ratings shift for Laurentian Bank & Neumora Therapeutics. Royal Bank of Canada maintains "outperform" for Cameco. Dollar declines amid tariff concerns. Read more...

Analysts issue earnings forecasts for SBC Medical, Nuvalent, and Intrusion, while OptimumBank prepares to announce quarterly results. Logitech announces a share buyback program. Read more...

A summary of recent business news, including an Italian tax investigation into Elon Musk and updates on several companies' stock ratings and earnings estimates. Read more...

Several institutional investors, including Principal Financial, Rhumbline Advisers, and Private Trust Co. NA, adjusted their stock holdings in Q4, impacting companies like Petco, Legend Biotech, and Centene Co. Analysts also updated earnings estimates for WESCO International and PEDEVCO. Read more...

Recent analyst activity includes a buy rating for Jamf and lowered earnings estimates for Fortrea, Verisk, Teladoc Health, and VSE, all involving insights from William Blair. CentralReach is also exploring a sale with William Blair's assistance. Read more...

Recent analyst reports show a mixed outlook for companies like Chegg, MasTec, Mohawk Industries, Titan International, and Butterfly Network, with ratings ranging from "Reduce" to increased investment. Read more...

A look at the week's business news, from zSpace earnings forecasts to French agricultural competitions, scam call centers, a new packaging levy in France, and the auction of Napoleon Bonaparte's Civil Code. Read more...

Tariffs on Canada, Mexico, and China trigger market risk aversion, while China focuses on state-owned bank capital. Gold shines as a safe haven amidst economic uncertainty. Read more...

Praxis faces a complex investment landscape. Despite a "Hold" rating and setbacks with Ulixacaltamide, the company presents a high-risk, high-reward opportunity in the epilepsy sector. Read more...